These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1137 related articles for article (PubMed ID: 8300123)
1. Anti-idiotypes in melanoma. Ferrone S Hybridoma; 1993 Oct; 12(5):509-14. PubMed ID: 8300123 [No Abstract] [Full Text] [Related]
2. Active specific immunotherapy of malignant melanoma with anti-idiotypic monoclonal antibodies. Ferrone S; Kageshita T; Hirai S J Dermatol; 1993 Sep; 20(9):533-9. PubMed ID: 8227707 [TBL] [Abstract][Full Text] [Related]
3. Association between induction of anti high molecular weight-melanoma associated antigen (HMW-MAA) immunity with mouse antiidiotypic monoclonal antibody (MoAb) MK2-23 and prolongation of survival in patients with melanoma. Chen ZJ; Yang H; Liu CC; Mittelman A; Ferrone S Pigment Cell Res; 1992; Suppl 2():113-22. PubMed ID: 1409413 [No Abstract] [Full Text] [Related]
4. Immunotherapy of melanoma: peptide mimics of a human high molecular weight-melanoma associated antigen. Wang X; Luo W; Ferrone S Medicina (B Aires); 2000; 60 Suppl 2():48-50. PubMed ID: 11188931 [TBL] [Abstract][Full Text] [Related]
5. Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Mittelman A; Wang X; Matsumoto K; Ferrone S Hybridoma; 1995 Apr; 14(2):175-81. PubMed ID: 7590776 [TBL] [Abstract][Full Text] [Related]
6. [Clinical trial of anti-idiotypic monoclonal antibodies in advanced melanoma]. Kageshita T; Hirai S; Ono T Gan To Kagaku Ryoho; 1994 Feb; 21(2):163-9. PubMed ID: 8311486 [TBL] [Abstract][Full Text] [Related]
7. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma. Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036 [TBL] [Abstract][Full Text] [Related]
8. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Mittelman A; Chen ZJ; Yang H; Wong GY; Ferrone S Proc Natl Acad Sci U S A; 1992 Jan; 89(2):466-70. PubMed ID: 1731316 [TBL] [Abstract][Full Text] [Related]
9. Immunological approaches to tumor therapy. Monoclonal antibodies, tumor vaccines, and anti-idiotypes. Hellström KE; Hellström I Targeted Diagn Ther; 1989; 2():1-39. PubMed ID: 2519542 [No Abstract] [Full Text] [Related]
10. Clinical trials with VMO for melanoma. Wallack MK; Sivanandham M Ann N Y Acad Sci; 1993 Aug; 690():178-89. PubMed ID: 8368736 [No Abstract] [Full Text] [Related]
11. Idiotypic cascade in the human high molecular weight melanoma-associated antigen system: fine specificity and idiotypic profile of anti-anti-idiotypic monoclonal antibodies. Yang H; Chen ZJ; Kageshita T; Yamada M; Ferrone S Eur J Immunol; 1993 Jul; 23(7):1671-7. PubMed ID: 7686858 [TBL] [Abstract][Full Text] [Related]
12. Augmentation of T-cell response with a melanoma cell vaccine expressing specific HLA-A antigens. Hoon DS; Morisaki T; Uchiyama A; Hayashi Y; Foshag LJ; Nizze AJ; Morton DL Ann N Y Acad Sci; 1993 Aug; 690():343-5. PubMed ID: 8368751 [No Abstract] [Full Text] [Related]
13. Improved tumor targeting of rhenium-186-labeled anti-human high-m.w. melanoma-associated antigen monoclonal antibody 763.74 following purification with anti-idiotypic monoclonal antibody MK2-23. Hamby CV; Chinol M; Palestro CJ; Manzo C; Ferrone S Int J Cancer; 1998 Nov; 78(4):486-90. PubMed ID: 9797138 [TBL] [Abstract][Full Text] [Related]
14. Human high molecular weight-melanoma associated antigen as a target for active specific immunotherapy--a phase I clinical trial with murine antiidiotypic monoclonal antibodies. Ferrone S; Kageshita T J Dermatol; 1988 Dec; 15(6):457-65. PubMed ID: 3074088 [No Abstract] [Full Text] [Related]
15. Melanoma antigens: immunological and biological characterization and clinical significance. Herlyn M; Koprowski H Annu Rev Immunol; 1988; 6():283-308. PubMed ID: 3289568 [No Abstract] [Full Text] [Related]
16. Comparison of the binding parameters to melanoma cells of antihuman high molecular weight-melanoma associated antigen (HMW-MAA) monoclonal antibodies (mAb) and syngeneic anti-anti-idiotypic (anti-anti-id) mAb. Chen ZJ; Ferrone S Ann N Y Acad Sci; 1993 Aug; 690():398-401. PubMed ID: 8368768 [No Abstract] [Full Text] [Related]
17. Melanoma: the development of immunoconjugates from a preclinical viewpoint. Beaumier PL; Morgan AC; Woodhouse CS; Marchitto KS Immunol Ser; 1990; 53():297-316. PubMed ID: 2100562 [No Abstract] [Full Text] [Related]
18. Human tumor-associated antigen mimicry by anti-idiotypic antibodies. Immunogenicity and clinical trials in patients with solid tumors. Ferrone S Ann N Y Acad Sci; 1993 Aug; 690():214-24. PubMed ID: 8368740 [No Abstract] [Full Text] [Related]
19. [Active specific immunotherapy of cancer using anti-idiotypic monoclonal antibodies]. Castello G; D'Alessio V Clin Ter; 1991 May; 137(3):155-67. PubMed ID: 1831084 [TBL] [Abstract][Full Text] [Related]
20. Anti-tyrosinase antibodies participate in the immune response to vaccination with anti-idiotypic antibodies mimicking the high-molecular-weight melanoma-associated antigen. Baharav E; Merimsky O; Altomonte M; Shoenfeld Y; Pavlovic M; Maio M; Ferrone S; Fishman P Melanoma Res; 1995 Oct; 5(5):337-43. PubMed ID: 8541724 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]